266 related articles for article (PubMed ID: 28238756)
1. Gaps in Patient Knowledge About Risks and Benefits of Testosterone Replacement Therapy.
Gilbert K; Cimmino CB; Beebe LC; Mehta A
Urology; 2017 May; 103():27-33. PubMed ID: 28238756
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
3. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
4. A Pilot Study Using a Web Survey to Identify Characteristics That Influence Hypogonadal Men to Initiate Testosterone Replacement Therapy.
Rosen RC; Seftel AD; Ruff DD; Muram D
Am J Mens Health; 2018 May; 12(3):567-574. PubMed ID: 26819183
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Therapy: What We Have Learned From Trials.
Corona G; Torres LO; Maggi M
J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
[TBL] [Abstract][Full Text] [Related]
6. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
[TBL] [Abstract][Full Text] [Related]
8. Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
Maganty A; Osterberg EC; Ramasamy R
Am J Mens Health; 2015 Jul; 9(4):340-4. PubMed ID: 24972716
[TBL] [Abstract][Full Text] [Related]
9. Late-life onset hypogonadism: a review.
Bassil N; Morley JE
Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
[TBL] [Abstract][Full Text] [Related]
10. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone.
Chrysant SG; Chrysant GS
Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-Art: a Review of Cardiovascular Effects of Testosterone Replacement Therapy in Adult Males.
Elsherbiny A; Tricomi M; Bhatt D; Dandapantula HK
Curr Cardiol Rep; 2017 Apr; 19(4):35. PubMed ID: 28361372
[TBL] [Abstract][Full Text] [Related]
13. EMAS position statement: Testosterone replacement therapy in the aging male.
Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
15. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
17. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
Bacevičienė R; Valonytė L; Ceponis J
Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
19. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.
Shigehara K; Konaka H; Kato Y; Iijima M; Nakashima K; Kawaguchi S; Nohara T; Izumi K; Namiki M; Mizokami A
Int J Impot Res; 2019 Jan; 31(1):25-30. PubMed ID: 30135606
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy in males with erectile dysfunction.
Jacob BC
J Pharm Pract; 2011 Jun; 24(3):298-306. PubMed ID: 21676853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
